Polycrystalline is expanding its HPAPI offerings, up to OEB 5 level of containment for the synthesis, study and development of anti-cancer and cytotoxic APIs. Polycrystalline has invested in capacity, state of the art equipment, and people who have a passion for developing solutions for clients with complex chemistry challenges.
Continue Reading
PolyCrystalLine s.r.l. received the approval from French Health Ministry as a CRO for R&D activities, the French companies who use our services can benefit of a tax credit in compliance with the article 244 quater B of the French general code of taxes. (see the PDF attached)
Continue Reading
PolyCrystalLine received the audit from the Health Agency for the cGMP certification. PolyCrystalLine received the audit from the Health Agency for the cGMP certification. The authorization is granted on chemical/physics analyses for qualitative and quantitative determination of active ingredients, intermediates and finished products
Continue Reading
PolyCrystalLine discovered a novel crystalline form of Minodronic Acid and filed a patent application. For additional information contact info@polycrystalline.it
Continue Reading
Polycrystalline, CSV Life Science e Pharma-Hub organizzano la Giornata di Studio sul tema “SOSTANZE ALTAMENTE ATTIVE: RISCHI E CONTENIMENTO” che si terrà a Formia il giorno 05 Aprile 2018. Sedi delle giornate di studio Formia 1ª edizione 05 Aprile 2018 – Kora Park Hotel, Via Mergataro 04023 Formia (LT) Quota di partecipazione PARTECIPAZIONE GRATUITA FINO AD ESAURIMENTO POSTI Per info ed iscrizioni …
Continue Reading
